Kees Bol

871 total citations
10 papers, 537 citations indexed

About

Kees Bol is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Molecular Biology. According to data from OpenAlex, Kees Bol has authored 10 papers receiving a total of 537 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 7 papers in Radiology, Nuclear Medicine and Imaging and 5 papers in Molecular Biology. Recurrent topics in Kees Bol's work include HER2/EGFR in Cancer Research (6 papers), Monoclonal and Polyclonal Antibodies Research (6 papers) and Glycosylation and Glycoproteins Research (2 papers). Kees Bol is often cited by papers focused on HER2/EGFR in Cancer Research (6 papers), Monoclonal and Polyclonal Antibodies Research (6 papers) and Glycosylation and Glycoproteins Research (2 papers). Kees Bol collaborates with scholars based in Netherlands, United States and Spain. Kees Bol's co-authors include Alain Thibault, Judith E. Karp, David W. End, Ivana Gojo, R. T. Belly, W. Edward Highsmith, Ivan D. Horak, Timothy Kottke, Michael L. Tidwell and Raymond J. Hohl and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Kees Bol

10 papers receiving 517 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Kees Bol Netherlands	7	283	259	225	132	89	10	537
Mecide Gharibo United States	12	197 0.7×	175 0.7×	146 0.6×	67 0.5×	57 0.6×	34	400
Amy Camuso United States	9	163 0.6×	113 0.4×	162 0.7×	70 0.5×	114 1.3×	12	402
Koorosh Korfi United Kingdom	8	148 0.5×	228 0.9×	241 1.1×	42 0.3×	151 1.7×	18	549
Ka Lung Wu Belgium	14	361 1.3×	287 1.1×	344 1.5×	76 0.6×	210 2.4×	39	708
Krista Fager United States	8	135 0.5×	113 0.4×	161 0.7×	69 0.5×	114 1.3×	11	374
Sreeni Yalamanchili United States	8	440 1.6×	266 1.0×	64 0.3×	80 0.6×	80 0.9×	17	634
Joy Knight United States	8	288 1.0×	247 1.0×	123 0.5×	113 0.9×	181 2.0×	13	633
Sarah E. Dorff United States	4	177 0.6×	117 0.5×	56 0.2×	96 0.7×	45 0.5×	5	364
Josephine L. Klitgaard United States	7	133 0.5×	178 0.7×	108 0.5×	28 0.2×	171 1.9×	11	426
James Berenson United States	11	250 0.9×	310 1.2×	207 0.9×	53 0.4×	100 1.1×	23	564

Countries citing papers authored by Kees Bol

Since Specialization

Citations

This map shows the geographic impact of Kees Bol's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kees Bol with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kees Bol more than expected).

Fields of papers citing papers by Kees Bol

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kees Bol. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kees Bol. The network helps show where Kees Bol may publish in the future.

Co-authorship network of co-authors of Kees Bol

This figure shows the co-authorship network connecting the top 25 collaborators of Kees Bol. A scholar is included among the top collaborators of Kees Bol based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kees Bol. Kees Bol is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

10 of 10 papers shown

Kyi, Chrisann, Sylvie Rottey, Ignacio Melero, et al.. (2024). Phase I study of MCLA-145, a bispecific antibody targeting CD137 and PD-L1, in solid tumors, as monotherapy or in combination with pembrolizumab.. Journal of Clinical Oncology. 42(16_suppl). 2520–2520. 4 indexed citations

Argilés, Guillem, Christiane Jungels, Rocio García‐Carbonero, et al.. (2021). Phase I dose-escalation study of MCLA-158, a first-in-class bispecific antibody targeting EGFR and LGR5, in metastatic colorectal cancer (CRC).. Journal of Clinical Oncology. 39(3_suppl). 62–62. 5 indexed citations

Bol, Kees, Robert P. Doornbos, Anastasia Murat, et al.. (2020). Population Pharmacokinetics of MCLA-128, a HER2/HER3 Bispecific Monoclonal Antibody, in Patients with Solid Tumors. Clinical Pharmacokinetics. 59(7). 875–884. 17 indexed citations

Hamilton, Erika, Thierry Petit, Barbara Pistilli, et al.. (2020). Clinical activity of MCLA-128 (zenocutuzumab), trastuzumab, and vinorelbine in HER2 amplified metastatic breast cancer (MBC) patients (pts) who had progressed on anti-HER2 ADCs.. Journal of Clinical Oncology. 38(15_suppl). 3093–3093. 28 indexed citations

Bol, Kees, Wilfred E. Marissen, Paul J. Tacken, et al.. (2020). 814 MCLA-145 (CD137xPD-L1): a potent CD137 agonist and immune checkpoint inhibitor that that does not show signs of peripheral toxicity. SHILAP Revista de lepidopterología. A487.1–A487. 2 indexed citations

Pistilli, Barbara, Hans Wildiers, Erika Hamilton, et al.. (2020). Clinical activity of MCLA-128 (zenocutuzumab) in combination with endocrine therapy (ET) in ER+/HER2-low, non-amplified metastatic breast cancer (MBC) patients (pts) with ET-resistant disease who had progressed on a CDK4/6 inhibitor (CDK4/6i).. Journal of Clinical Oncology. 38(15_suppl). 1037–1037. 31 indexed citations

Doornbos, Robert P., Alexander B. H. Bakker, Kees Bol, et al.. (2018). Translational PK-PD modeling analysis of MCLA-128, a HER2/HER3 bispecific monoclonal antibody, to predict clinical efficacious exposure and dose. Investigational New Drugs. 36(6). 1006–1015. 31 indexed citations

Alsina, María, Valentina Boni, Jan H.M. Schellens, et al.. (2017). First-in-human phase 1/2 study of MCLA-128, a full length IgG1 bispecific antibody targeting HER2 and HER3: Final phase 1 data and preliminary activity in HER2+ metastatic breast cancer (MBC).. Journal of Clinical Oncology. 35(15_suppl). 2522–2522. 40 indexed citations

Calvo, Emiliano, María Alsina, Jan H.M. Schellens, et al.. (2016). Abstract CT050: A Phase I/II Study of MCLA-128, a full length IgG1 Bispecific Antibody Targeting HER2 and HER3, in Patients with Solid Tumors. Cancer Research. 76(14_Supplement). CT050–CT050. 12 indexed citations

10.

Karp, Judith E., Jeffrey E. Lancet, Scott H. Kaufmann, et al.. (2001). Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial. Blood. 97(11). 3361–3369. 367 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact